Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 2
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Items 701–800 of 910
Clinical Significance of HIV-Associated Bone Loss: When and How to Intervene
Yin, M. T., Shane, E. J., & Anastos, K. (2008) · Future HIV Therapy · doi:10.2217/17469600.2.5.465 · Cited by 1
Self-citationOsteoporosis for the practicing neurologist
Shubhakaran, K., & Khichar, R. J. (2014) · Neurology Clinical Practice · doi:10.1212/01.cpj.0000451407.84778.b0
Treatment and Prevention of Glucocorticoid-Induced Osteoporosis
Micheletti, R. G., Murrell, D. F., & Werth, V. P. (2015) · Springer eBooks · doi:10.1007/978-3-662-45698-9_63 · Cited by 2
Principles and Guidelines of Immunotherapy in Neuromuscular Disorders
Mitchell, C. W., & Bertorini, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0372-6.00007-4 · Cited by 1
Comorbidity in Rheumatoid Arthritis
Esdaile, J. M., Goycochea, M., & Lacaille, D. V. (2009) · Elsevier eBooks · doi:10.1016/b978-032305475-1.50015-x · Cited by 1
Osteoporosis in Rheumatologic Conditions and Inflammatory Disorders
Oleson, C. V. (2017) · Springer eBooks · doi:10.1007/978-3-319-45084-1_12 · Cited by 1
A History of the Parathyroid Glands and their Secretory Product, Parathyroid Hormone
Nordenström, J., & Marcus, R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397166-1.00064-3 · Cited by 1
Self-citationAnabolic Agents for the Treatment of Postmenopausal Osteoporosis
Minisola, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-13936-0_25 · Cited by 1
Qiu, M., Ding, L., Zhang, M., Lin, J.-H., Huang, H., & Li, K. (2020) · Medicine · doi:10.1097/md.0000000000022690 · Cited by 2
Osteoporosis Treatment Success and Failure
Lewiecki, E. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-83951-2_16 · Cited by 2
Costa, A. G., Cusano, N. E., Silva, B. C. C., & Bilezikian, J. P. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_25 · Cited by 1
Rosen, C. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00251-7 · Cited by 1
Osteoporosis for the practicing neurologist
Rothman, M. S., West, S. G., & McDermott, M. T. (2014) · Neurology Clinical Practice · doi:10.1212/01.cpj.0000437349.39987.fa · Cited by 1
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Rife, E. C., Abdalla, J. E., de la Rocha, J. L., & Emejuaiwe, N. (2023) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-023-01392-5 · Cited by 1
Gu, Y., Gao, Y., Yang, Z., Ni, J., & He, G. (2023) · Endokrynologia Polska · doi:10.5603/ep.a2022.0035 · Cited by 1
GLUCOCORTICOIDS IN CHRONIC DISEASE: THE GOOD, THE BAD, THE BONE.
Saag, K. G. (2023) · PubMed Central · Cited by 6
Self-citationLim, S. Y. (2023) · Tissue repair and reconstruction · doi:10.1007/978-981-99-5826-9_4 · Cited by 1
Zhang, S., Hao, W., Chen, D., Chen, S., Li, Z., Wang, H., Zhong, F., Li, S., Wang, J., Zhan, Z., et al. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149888 · Cited by 1
Toroptsova, N. V., & Nasonov, E. L. (2024) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2024-145-153 · Cited by 1
Current and Upcoming Treatments for Osteoporosis
Chung, Y. (2012) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2012.19.1.4 · Cited by 1
Management of Male Osteoporosis: an Update
Almohaya, M. S., Alobedollah, A., & Kendler, D. L. (2018) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-018-0107-1 · Cited by 1
Pilz, S., Tomaschitz, A., & März, W. (2019) · CME · doi:10.1007/s11298-019-6899-y · Cited by 1
Basic and clinical aspects of glucocorticoid action in bone
Zhou, H., Cooper, M. S., & Seibel, M. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00039-7 · Cited by 1
Osteoporosis in premenopausal women, pregnancy, and lactation
Nair, N., Liu, M., & Cohen, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00038-1 · Cited by 1
Osteoporosis in childhood and adolescence
Nasomyont, N., & Gordon, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00037-x · Cited by 1
Cellini, M., Biamonte, E., Lania, A. G., & Mazziotti, G. (2020) · L Endocrinologo · doi:10.1007/s40619-020-00768-2 · Cited by 2
Hsu, H.-E., Hsu, Y.-P., & Yu, C. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05880-z · Cited by 1
New possibilities for the treatment of glucocorticoid-induced osteoporosis
Baranova, I. A. (2014) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2014-2-107-110 · Cited by 1
Geroscience and Management of Osteoporosis in Older Adults
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_19 · Cited by 1
Glucocorticoid-Induced Osteoporosis
Mazziotti, G., CANALIS, E. M., & Bilezikian, J. P. (2022) · doi:10.1093/med/9780198870197.003.0092 · Cited by 1
Osteoporosis inducida por glucocorticoides
Mercier-Guery, A. (2024) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(24)49761-x · Cited by 1
Glucocorticoid-induced Osteoporosis: From Pathogenesis to Treatment
Chung, Y. (2009) · AJOU Open Repository (Ajou University) · Cited by 1
Treatment of Male Osteoporosis with Parathyroid Hormone
Girotra, M., Cosman, F., & Bilezikian, J. P. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00055-9 · Cited by 1
Ursache und Verlauf der Bisphosphonat assoziierten Kiefernekrose
Ripperger, J. (2011) · Cited by 1
Parathyroid Hormone: Anabolic Treatment of Osteoporosis
Eriksen, E. F. (2013) · Wiley eBooks · doi:10.1002/9781118316290.ch11 · Cited by 2
Pereira, I. A. (2012) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042012000400001 · Cited by 4
Bisphosphonates in Patients with Glucocorticoids: Time for Implementation
Lems, W. F. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090535 · Cited by 1
Teriparatide or Alendronate in Glucocorticoid-Induced
Cross, T., Berry, P. A., & Burroughs, A. K. (2008) · Cited by 1
Hwang, Y. G., & Saag, K. G. (2013) · doi:10.2217/ebo.12.223 · Cited by 1
Self-citationERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS
Jung, N., Mayet, W.-J., Mertens, P. R., Meyer, J. S., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50015-2 · Cited by 1
Osteoporosis in rheumatic diseases
Evstigneeva, L. P. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-33-64-75 · Cited by 1
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32831c7e5c · Cited by 1
Parathyroid Hormone and Abaloparatide Treatment for Osteoporosis
Cosman, F., & Greenspan, S. L. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch73 · Cited by 1
Falciani, C., Pini, A., & Bracci, L. (2011) · Wiley eBooks · doi:10.1002/9783527631827.ch7 · Cited by 2
Minisola, S., & Romagnoli, E. (2009) · Springer eBooks · doi:10.1007/978-88-470-1357-5_48 · Cited by 1
Metabolic Bone Disease Following Organ Transplantation
Kim, S., Epstein, S., Yuen, T., Pazianas, M., Sun, L., Murphy, B. T., & Zaidi, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19905-4_10
Scharla, S. H., Oertel, H., Jakob, F. J., & Petto, H. (2013) · Osteologie/Osteology · doi:10.1055/s-0038-1630119
Estudio del metabolismo mineral óseo en el cáncer de próstata avanzado
Flores, S. Q. (2011) · Institutional Repository of the University of Granada (University of Granada)
Metabolic Bone Disease in Gastrointestinal Disorders
Cranney, A., Dube, C., Rostom, A., Tugwell, P., & Wells, G. A. (2004) · Wiley eBooks · doi:10.1002/9780470987025.ch14
Function of cells producing type I collagen: potentialinfluence of the vasculature
Taylor, S. E. B. (2011) · UCL Discovery (University College London)
Pfeifer, M. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50325-3
Metabolic and Endocrine Management of the Organ Transplant Recipient
Issa, N. S., Reule, S. A., & Kukla, A. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch100
Role of Primary Care Provider in the Referral and Care of Thoracic Organ Transplant Patients
Bag, R., Bhimaraj, A., & Garikipati, S. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch35
Comment je traite une ostéoporose au cours d'un lupus érythémateux ?
Roux, C. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-71447-4.50032-5
Writers, A. M. (2012) · Drugs & Therapy Perspectives · doi:10.1007/s40267-012-0003-y
Almirol, E. A. (2013) · OpenBU (Boston University) · Cited by 1
Wang, Y.-T., Chuang, L., & Lu, C. (2015) · RSC Advances · doi:10.1039/c5ra10068b
Lebererkrankungen und Osteoporose
Gaugg, M., & Erlacher, L. (2011) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Women’s Bone Health: Breathing Life into the Skeleton
Seton, M. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4712-1_3
Le tériparatide ou l’alendronate dans l’ostéoporose induite par les corticostéroïdes
Gélinas-Lemay, É. (2008) · Pharmactuel
Anabole therapie met teriparatide bij door glucocorticosteroïden veroorzaakte osteoporose
Bruijnzeel, P. L. B. (2008) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03076999
Teriparatide for Glucocorticoid-induced Osteoporosis
Díez‐Pérez, A., & Solé, E. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.111629
Recurrent fractures in an elderly patient with systemic lupus erythematosus
Chia, F. L., Thong, B. Y., Tang‐Ching, L. A. U., & Pao‐Hsii, F. E. N. G. (2009) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2009.01422.x
Lopes, R. F., Marchesi, A. O., Fossari, R. N., Cezar, M. C., Coeli, C. M., & Farias, M. L. F. (2009) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042009000400007 · Cited by 7
Seguimiento y tratamiento de la osteoporosis inducida por glucocorticoides
Montes, J. D. P., Ferreras, R. P., González, M. D. S., Pérez, A. C., & González, R. (2010) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(10)70180-3
Teriparatide delivery by indwelling MicroChip
Cosman, F. (2012) · IBMS BoneKEy · doi:10.1038/bonekey.2012.195
Caring for adults with cystic fibrosis
Anstead, M. (2010) · International Journal on Disability and Human Development · doi:10.1515/ijdhd.2010.017
Review of Comparative Effectiveness of Treatments to Prevent Fractures
Stock, J. L., Mershon, J. L., & Schoenfeld, M. J. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00018
Les bisphosphonates dans l’ostéoporose cortico-induite : efficacité et tolérance
Lespessailles, É. (2013) · Revue du Rhumatisme · doi:10.1016/j.rhum.2012.09.006
Osteoporosis inducida por corticoides
Marcelli, C. (2011) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(11)71143-1
Bone imaging and strength in chronic obstructive pulmonary disease
Romme, E. A. (2014) · Research Publications (Maastricht University) · doi:10.26481/dis.20140220er
Osteoporosis secundaria. tratamiento actualizado
Oviedo, G. S. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70227-x · Cited by 4
Iatrogenic osteoporosis in dermatology
Foo, C. W., Yukumoto, E., DeJournett, R., & Johnson, D. W. (2009) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2009.04190.x
Karnik, A. A., & Feldt, J. M. V. (2008) · Aging Health · doi:10.2217/1745509x.4.4.351
Lane, J. M. (2015) · The Spine Journal · doi:10.1016/j.spinee.2014.11.009
Osteoporosis en enfermedades reumáticas
Gabrielli, S. H. J., & Campusano, M. C. (2012) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(12)70333-4
Osteoporosis y Metabolismo Mineral
Díez Pérez, A., Manteca, L. A., Izquierdo Delgado, E., Andrés Calvo, M., Vega Tejedor, G., Mendo González, M., Jl, P. C., Ivorra Cortés, J., Ivorra, R., Jj, A. S., et al. (2010)
Teriparatide in the treatment of postmenopausal osteoporosis
Interna, S. D. M. (2010)
Basak, R. C., Chatterjee, M., & Rasem, M. W. (2009) · Cited by 1
osteoporosis: an update on current pharmacotherapy and future directions
Bultink, I. E. M., Baden, M., & Lems, W. F. (2013)
Glukokortikoidi v nefrologiji I: farmakologija in stranski učinki
Pajek, J., & Jensterle, M. (2015) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1236 · Cited by 1
This is to certify that the thesis/dissertation prepared
Hoblitzell, A., Mukhopadhyay, S., & Xia, Y. (2010)
Brance, M. L., & Plantalech, L. (2014) · Revista Argentina de Reumatología · doi:10.47196/rar.v25i3.87 · Cited by 1
Callen, J. P. (2007) · Journal watch · doi:10.1056/jd200711140000001
Brance, M. L., & Plantalech, L. (2013) · Actualizaciones en osteología · Cited by 1
Parathyroid Hormone vs. Alendronate for Steroid-Induced Osteoporosis
Brett, A. S. (2007) · Journal watch · doi:10.1056/jw200711270000002
Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
de Reumatología, S., de Haya, C. T., & la Investigación, U. D. R. D. I. C. P. (2011)
The Impact of Regulatory and Scientific Organizations’ Recommendations on Clinical Decision-Making
Παπαϊωάννου, Α., Agarwal, A., & Karampatos, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-23639-1_21
Clinical Skeletal Syndromes Associated with Parathyroid Disorders in Chronic Kidney Disease
Miller, P. D., Jamal, S. A., & Sprague, S. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397166-1.00045-x
Parathyroid Hormone as Monotherapy for the Treatment of Osteoporosis
Cosman, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397166-1.00060-6
New Approaches to Osteoporosis Therapeutics
Costa, A. G., Cusano, N. E., Silva, B. C. C., & Bilezikian, J. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00086-8
Parathyroid Hormone and Glucocorticoid-induced Osteoporosis
Adler, R. A., & Giustina, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397166-1.00059-x
Baschant, U., Stein, M., & Tuckermann, J. P. (2016) · Osteologie/Osteology · doi:10.1055/s-0037-1619028
Auszug der Leitlinieninhalte 2014 bezüglich einer Glukokortikoidtherapie: DVO-Leitlinie Osteoporose
Siggelkow, H. (2016) · Osteologie/Osteology · doi:10.1055/s-0037-1619031
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.